Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients

Trial Profile

Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2011

At a glance

  • Drugs Lamivudine (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top